Education
About Us
Working with TipRanks
Follow Us
Charles River Laboratories Intl (CRL)
NYSE:CRL
CRL Analyst Ratings
Hold
0 Buy
14 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CRL Stock 12 Month Forecast
Average Price Target
$176.08
▲(11.40% Upside)
| Highest Price Target$188.00 | Average Price Target$176.08 | Lowest Price Target$165.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Goldman Sachs
Downgraded
03/21/25
Jefferies
Reiterated
03/20/25
Redburn Atlantic
Upgraded
03/03/25
Evercore ISI
Reiterated
02/24/25
TD Cowen
Reiterated
02/23/25
Morgan Stanley
Reiterated
02/21/25
Robert W. Baird
Reiterated
02/20/25
J.P. Morgan
Reiterated
02/20/25
Bank of America Securities
Reiterated
02/19/25
Mizuho Securities
$210→$175
Hold
10.72%
Upside
Reiterated
02/18/25
Charles River Labs (CRL) PT Lowered to $175 at MizuhoMizuho analyst Ann Hynes lowered the price target on Charles River Labs (NYSE: CRL) to $175.00 (from $210.00) while maintaining a Neutral rating.
Barclays
$166
Hold
5.02%
Upside
Reiterated
02/18/25
Analysts Are Neutral on Top Healthcare Stocks: DaVita (DVA), Exelixis (EXEL)
William Blair
―
Hold
―
Downgraded
01/22/25
Charles River downgraded to Market Perform from Outperform at William BlairCharles River downgraded to Market Perform from Outperform at William Blair
UBS
$250→$185
Hold
17.04%
Upside
Downgraded
01/17/25
Charles River downgraded to Neutral from Buy at UBSCharles River downgraded to Neutral from Buy at UBS
CLSA
$164
Sell
3.76%
Upside
Downgraded
11/18/24
CLSA downgrades Charles River Labs (CRL) to Underperform (4)
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Goldman Sachs
Downgraded
03/21/25
Jefferies
Reiterated
03/20/25
Redburn Atlantic
Upgraded
03/03/25
Evercore ISI
Reiterated
02/24/25
TD Cowen
Reiterated
02/23/25
Morgan Stanley
Reiterated
02/21/25
Robert W. Baird
Reiterated
02/20/25
J.P. Morgan
Reiterated
02/20/25
Bank of America Securities
Reiterated
02/19/25
Mizuho Securities
$210→$175
Hold
10.72%
Upside
Reiterated
02/18/25
Charles River Labs (CRL) PT Lowered to $175 at MizuhoMizuho analyst Ann Hynes lowered the price target on Charles River Labs (NYSE: CRL) to $175.00 (from $210.00) while maintaining a Neutral rating.
Barclays
$166
Hold
5.02%
Upside
Reiterated
02/18/25
Analysts Are Neutral on Top Healthcare Stocks: DaVita (DVA), Exelixis (EXEL)
William Blair
―
Hold
―
Downgraded
01/22/25
Charles River downgraded to Market Perform from Outperform at William BlairCharles River downgraded to Market Perform from Outperform at William Blair
UBS
$250→$185
Hold
17.04%
Upside
Downgraded
01/17/25
Charles River downgraded to Neutral from Buy at UBSCharles River downgraded to Neutral from Buy at UBS
CLSA
$164
Sell
3.76%
Upside
Downgraded
11/18/24
CLSA downgrades Charles River Labs (CRL) to Underperform (4)
CRL Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
0
0
0
0
0
Buy
3
2
3
1
1
Hold
15
15
21
23
25
Sell
5
5
3
1
1
Strong Sell
0
0
0
0
0
total
23
22
27
25
27
Each month's total comprises the sum of three months' worth of ratings.
CRL Financial Forecast
CRL Stock Forecast FAQ
What is CRL’s average 12-month price target, according to analysts?
Based on analyst ratings, Charles River Laboratories Intl’s 12-month average price target is $176.08.
What is CRL’s upside potential, based on the analysts’ average price target?
Charles River Laboratories Intl has 11.40% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CRL a Buy, Sell or Hold?
Charles River Laboratories Intl has a consensus rating of Hold which is based on 0 buy ratings, 14 hold ratings and 0 sell ratings.
What is Charles River Laboratories Intl’s price target?
The average price target for Charles River Laboratories Intl is $176.08. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $188.00 ,the lowest forecast is $165.00. The average price target represents 11.40% Increase from the current price of $158.06.
The highest analyst price target is $188.00 ,the lowest forecast is $165.00. The average price target represents 11.40% Increase from the current price of $158.06.
What do analysts say about Charles River Laboratories Intl?
Charles River Laboratories Intl’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of CRL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.